Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago

Current Kidney Transplant - Clinical Trials

Project Title:

Noninvasive Diagnosis of Renal Allograft Rejection by Urinary Cell mRNA Profiling (CTOT-04)

Purpose:

The purpose of this study is to find a way to see if rejection is about to occur. We are looking at mRNA levels in urine samples to see if they predict the development of acute rejection. Taking part in this study requires blood and/or urine samples over a 36-month period.

Inclusion criteria:

  • Male and female recipients of all races, 0 to 80 years of age
  • Patients undergoing primary or re-do living or deceased donor kidney transplantation
  • Ability to provide informed consent

Sponsor:

NIAID/NIH

Principal Investigator:

Michael Abecassis, MD 

Cost:

None

Contact:

Jane Charette, RN
312-503-0256


Project Title:

Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients after T Cell Depletion with Alemtuzumab (anti-CD52 monoclonal antibody). Potential Implications for Safe Immunosuppression minimization

Purpose:

The purpose of this study is to discover how the immunosuppressive medication, alemtuzumab (Campath-1H), affects the B and T cells of your immune system. By looking at these cells using a number of laboratory tests, we may be able to determine how many of these cells are actively working. This study will enroll 50 newly transplanted subjects and take place over a 12 to 18 month period.

Inclusion trial criteria:

  • Adult subjects between ages 18 to 65 of either gender
  • Recipients have an available ABO compatible living donor for transplant
  • Subjects are listed to be a single-organ recipient (kidney only)
  • Subjects have the ability to provide informed consent

Sponsor:

American Society of Transplantation Grant

Principal Investigator:

Lorenzo Gallon, MD 

Cost:

None

IRB Project Number:

0773-011

Contact:

Linda B. Roberts, RN
312-503-0252


Project Title:

A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined with Prednisone-Free and Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation. "Cell 220"

Purpose:

The purpose of this study is to evaluate the efficacy and safety of a combined prednisone-free and calcineurin-inhibitor-free immunosuppression protocol in kidney transplantation. Also, the investigator seeks to assess the incidence and characteristics of biopsy-proven acute allograft rejection in the first 6 months post-transplant. This study seeks to enroll 45 subjects who will be followed over a 12-month period. Inclusion trial criteria: Subjects with end-stage renal disease (ESRD) who undergo a living donor kidney transplant.

Inclusion trial criteria:

Subjects with end-stage renal disease (ESRD) who undergo a living donor kidney transplant

Sponsor:

Roche

Principal Investigator:

Joseph Leventhal, MD, PhD 

Cost:

None

Contact:

Karen Matijevich
312-503-5213

IRB Project Number:

0811-007

Last UpdateDecember 3, 2012

Appointments

For more information or to make an appointment please call 312-695-0828.

top